-
AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy
•
Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series B financing round, following a USD 37 million Series A funding in July this year. This latest round was led by HanKang Capital, with participation from Sherpa Capital, CDH Investments, and a strategic investor, along…
-
AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137
•
AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37 million in a Series A financing round. The round was spearheaded by the InnoPinnacle Fund, with additional investments from a consortium that includes Yuanbio Venture Capital, Hankang Capital, Qiming Venture Partners, and Genesis Capital. The…
-
AusperBio and Asymchem Form Strategic Partnership for Drug Development
•
China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership focusing on new drug R&D technical services, drug administration and regulation consultation, brand linkage communication, and more. This collaboration aims to enhance their capabilities in the pharmaceutical sector by leveraging each other’s strengths. Background of…
-
AusperBio and Asymchem Form Strategic Partnership for New Drug R&D and Services
•
China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership to enhance their collaboration in new drug R&D technical services, drug administration and regulation consultation, brand linkage communication, and more. This partnership builds on their existing collaboration, which has already yielded significant results in the…
-
Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval
•
Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its joint venture Chongqing Mingdao Haoyue Biotechnology Co., Ltd has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its nasal spray COVID-19 neutralizing antibody MY-586. Drug Mechanism and AdvantagesMY-586 is described as…
